Zorevunersen in Children and Adolescents with Dravet Syndrome

Topic: Dravet Syndrome Presentations

Zorevunersen in Children and Adolescents with Dravet Syndrome

The New England Journal of Medicine

March 4, 2026

Zorevunersen continues to demonstrate potential as a disease-modifying therapy in long-term open-label extension studies of patients with Dravet syndrome

AES 2025

December 5, 2025

View Presentation

Zorevunersen continues to demonstrate potential as a disease-modifying therapy in long-term open-label extension studies of patients with Dravet syndrome

AES 2025

December 5, 2025

View Poster

Zorevunersen demonstrates disease-modifying potential in patients with Dravet syndrome with increases in seizure-free days, improvements in quality of life, and benefits in overall clinical status

AES 2025

December 5, 2025

View Poster

Spectral electroencephalogram abnormalities across development in patients with Dravet syndrome

AES 2025

December 5, 2025

View Poster

Electrophysiological improvements in patients with Dravet syndrome following treatment with zorevunersen, an investigational antisense oligonucleotide

AES 2025

December 5, 2025

View Poster

Zorevunersen demonstrates disease-modifying potential in patients with Dravet syndrome through durable seizure reduction and continuing improvements in cognition, behavior, and functioning through 36 months of treatment in open-label extension studies

CNS 2025

October 9, 2025

View Poster

Substantial improvements in overall seizure burden and seizure-free days in patients with Dravet syndrome treated with zorevunersen: Results from Phase 1/2a and open‑label extension studies

IEC 2025

September 1, 2025

View Poster

EMPEROR Phase 3 study design: Evaluation of zorevunersen as a potential disease-modifying therapy for Dravet syndrome

IEC 2025

September 1, 2025

View Poster

Zorevunersen demonstrates potential as a disease-modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and functioning with up to 36 months of maintenance dosing in open-label extension studies

IEC 2025

August 31, 2025

View Presentation